19 March 2024
Time to Look Upstream and Hold the US Alzheimer’s Association Accountable for Its Actions
The US Alzheimer’s Association provides critically important support services, education, programs, and referral services to countless individuals living with dementia, their families, and care professionals. It is making a real and meaningful difference in the lives of these people.
27 February 2024
Comment on Unleashing the Power of Bayesian Re-Analysis
I want to comment on the paper by Costa and colleagues on a Bayesian re-analysis of the Lecanemab phase 3 Clarity trial [1]. Costa and colleagues had already very meritoriously presented a Bayesian meta-analysis of the Aducanumab Phase 3 trials [2]. They contribute to a growing field of research that adopts Bayesian approaches to overcome limitations of frequentist p-value based statistical inference [3].
27 February 2024
Comment on Aluminum and Amyloid-in Familial Alzheimer’s Disease
I am writing to you regarding your recent call for feedback on the manuscript titled “Aluminum and Amyloid-in Familial Alzheimer’s Disease” by Mold and colleagues [1] that you have submitted on PubPeer (https://pubpeer.com/publications/1F23A5E2AE061A909F4D46F4919B50).
13 December 2023
Comment on The MedWalk Randomized Controlled Trial Experimental Protocol
I congratulate the authors of the study “A Mediterranean Diet and Walking Intervention to Reduce Cognitive Decline and Dementia Risk in Independently Living Older Australians: The MedWalk Randomized Controlled Trial Experimental Protocol, Including COVID-19 Related Modifications and Baseline Characteristics” published in the Journal of Alzheimer's Disease [1], for developing and contributing to the field of non-pharmacological interventions and lifestyle changes to reduce the risk of dementia and Alzheimer's disease in older adults.
12 July 2023
Cognitive function in patients with type 2 diabetes mellitus: a risk assessment
Chen et al. conducted a prospective study to investigate the association between type 2 diabetes mellitus (T2DM) status and cognitive function among middle-aged and older adults [1]. Although T2DM was not significantly associated with overall cognitive function, a significant association between glycemic status and overall cognitive function in patients with untreated T2DM. The authors concluded that screening and early treatment for T2DM were important for keeping better cognitive function in later life. I have some comments about the study.
9 July 2023
The Amyloid Hypothesis: The Greatest Invention or the Biggest Blunder in Biomedical Science Ever?
Understanding and treatment of disease go hand in hand. Despite decades of research efforts in academia and the drug industry, and hundreds of clinical trial studies, we have no treatment, and no prevention for Alzheimer's disease (AD). Why is that? The short answer is that we do not understand AD, its origin and disease mechanisms.
26 April 2023
Is there a clinically meaningful association between psoriasis and dementia?
Zingel et al. reported an association between psoriasis and dementia and concluded that patients with psoriasis should be advised about the relationship between psoriasis and the development of dementia [1]. With a sample size of over 20,000 patients and over 175,000 patient-years of follow up, the study had considerable power for detecting small differences in relative risk. They found that psoriasis was associated with a statistically significant 1.2-fold higher risk of developing dementia.
11 December 2022
Is Alzheimer’s Disease by Any Other Name Still Alzheimer’s Disease?
On November 1-2, 2022, PubMed listed over 190,000 entries for the search term “Alzheimer’s disease” (AD), with over 13,600 entries for 2022 alone [1], suggesting that this topic is highly researched by academics within the biomedical research community. In this letter, the topic of ‘tortured phrases’ [2], as applies to the term “Alzheimer’s disease”, is explored. Ultimately, the question is asked, if other terms are used to describe AD, would it still be recognized as such?
3 October 2022
Cetaceans: Models for Alzheimer's Disease?
Alzheimer's disease (AD), while being on one side the most frequently occurring dementia worldwide, cannot yet rely, conversely, on animal models encompassing the entire spectrum of its key pathological features, amyloid-β (Aβ) plaque-like aggregates and tau protein neurofibrillary tangles, in the brain tissue from affected patients [1].
19 January 2022
Response to the commentary “The Use of Standardized Diesel Exhaust Particles in Alzheimer’s Disease Research” by Block and Kodavanti
In their commentary on the suitability of the use of standardized diesel exhaust particles (DEP) for studying the adverse effects attributed to particulate matter (PM), Block and Kodavanti [1] refer to our recent publication by Farahani et al. [2] in which we offered experimental evidence on the dissimilarities in chemical composition of these DEP to ambient PM to which populations are exposed. The specific DEP is diesel soot emitted by a forklift engine (NIST SRM 2975). Parenthetically, we are not the first study to demonstrate this observation. For instance, Braun et al.
Pages
- Comment
|